Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug   candidate in oncology, ATYR2810, from its NRP2 antibody program.

Peer-reviewed paper supports aTyr’s antibody program . Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO , Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based

  Discovery advances the understanding of extracellular tRNA synthetase pathways . Findings may contribute to the development of new therapeutic s to treat cancer and fibrosis . SAN DIEGO , Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the

SAN DIEGO , Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide a

Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology . SAN DIEGO , Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative

SAN DIEGO , Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,

Top line results are expected in the fourth quarter of 202 0 . Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment . SAN DIEGO , Oct. 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and

SAN DIEGO , Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor events in

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers SAN DIEGO , Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel

Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel